148 related articles for article (PubMed ID: 33396520)
1. Hepatorenal Tyrosinaemia: Impact of a Simplified Diet on Metabolic Control and Clinical Outcome.
Bärhold F; Meyer U; Neugebauer AK; Thimm EM; Lier D; Rosenbaum-Fabian S; Och U; Fekete A; Möslinger D; Rohde C; Beblo S; Hochuli M; Bogovic N; Korpel V; Dahl SV; Mayorandan S; Fischer A; Freisinger P; Dokoupil K; Heddrich-Ellerbrok M; Jörg-Streller M; van Teeffelen-Heithoff A; Lahl J; Das AM
Nutrients; 2020 Dec; 13(1):. PubMed ID: 33396520
[No Abstract] [Full Text] [Related]
2. Natural Protein Tolerance and Metabolic Control in Patients with Hereditary Tyrosinaemia Type 1.
Yilmaz O; Daly A; Pinto A; Ashmore C; Evans S; Gupte G; Santra S; Preece MA; Mckiernan P; Kitchen S; Ayhan NY; MacDonald A
Nutrients; 2020 Apr; 12(4):. PubMed ID: 32325917
[TBL] [Abstract][Full Text] [Related]
3. Cross-sectional study of 168 patients with hepatorenal tyrosinaemia and implications for clinical practice.
Mayorandan S; Meyer U; Gokcay G; Segarra NG; de Baulny HO; van Spronsen F; Zeman J; de Laet C; Spiekerkoetter U; Thimm E; Maiorana A; Dionisi-Vici C; Moeslinger D; Brunner-Krainz M; Lotz-Havla AS; Cocho de Juan JA; Couce Pico ML; Santer R; Scholl-Bürgi S; Mandel H; Bliksrud YT; Freisinger P; Aldamiz-Echevarria LJ; Hochuli M; Gautschi M; Endig J; Jordan J; McKiernan P; Ernst S; Morlot S; Vogel A; Sander J; Das AM
Orphanet J Rare Dis; 2014 Aug; 9():107. PubMed ID: 25081276
[TBL] [Abstract][Full Text] [Related]
4. Long-term safety and outcomes in hereditary tyrosinaemia type 1 with nitisinone treatment: a 15-year non-interventional, multicentre study.
Spiekerkoetter U; Couce ML; Das AM; de Laet C; Dionisi-Vici C; Lund AM; Schiff M; Spada M; Sparve E; Szamosi J; Vara R; Rudebeck M
Lancet Diabetes Endocrinol; 2021 Jul; 9(7):427-435. PubMed ID: 34023005
[TBL] [Abstract][Full Text] [Related]
5. Diurnal variation of phenylalanine concentrations in tyrosinaemia type 1: should we be concerned?
Daly A; Gokmen-Ozel H; MacDonald A; Preece MA; Davies P; Chakrapani A; McKiernan P
J Hum Nutr Diet; 2012 Apr; 25(2):111-6. PubMed ID: 22168396
[TBL] [Abstract][Full Text] [Related]
6. Clinical utilization of dried blood spot nitisinone (NTBC) and succinylacetone (SA) concentrations in hereditary tyrosinaemia type 1 - A UK centre experience.
Yeo M; Turner C; Dalton NR; Rahman Y; Vara R
Ann Clin Biochem; 2020 Nov; 57(6):412-419. PubMed ID: 32936663
[TBL] [Abstract][Full Text] [Related]
7. Corneal depositions in tyrosinaemia type I during treatment with Nitisinone.
Wisse RP; Wittebol-Post D; Visser G; van der Lelij A
BMJ Case Rep; 2012 Nov; 2012():. PubMed ID: 23203167
[TBL] [Abstract][Full Text] [Related]
8. Predicting tyrosinaemia: a mathematical model of 4-hydroxyphenylpyruvate dioxygenase inhibition by nitisinone in rats.
Ward JP; Dunster JL; Derks G; Mistry P; Salazar JD
Math Med Biol; 2017 Sep; 34(3):335-390. PubMed ID: 27305933
[TBL] [Abstract][Full Text] [Related]
9. Phenylalanine supplementation improves the phenylalanine profile in tyrosinaemia.
Wilson CJ; Van Wyk KG; Leonard JV; Clayton PT
J Inherit Metab Dis; 2000 Nov; 23(7):677-83. PubMed ID: 11117429
[TBL] [Abstract][Full Text] [Related]
10. Nitisinone in the treatment of hereditary tyrosinaemia type 1.
McKiernan PJ
Drugs; 2006; 66(6):743-50. PubMed ID: 16706549
[TBL] [Abstract][Full Text] [Related]
11. Neuropsychological outcome of NTBC-treated patients with tyrosinaemia type 1.
De Laet C; Munoz VT; Jaeken J; François B; Carton D; Sokal EM; Dan B; Goyens PJ
Dev Med Child Neurol; 2011 Oct; 53(10):962-4. PubMed ID: 21745202
[No Abstract] [Full Text] [Related]
12. Tyrosinaemia type II: an easily diagnosed metabolic disorder with a rewarding therapeutic response.
al-Essa MA; Rashed MS; Ozand PT
East Mediterr Health J; 1999 Nov; 5(6):1204-7. PubMed ID: 11924112
[TBL] [Abstract][Full Text] [Related]
13. Dietary restriction of tyrosine and phenylalanine lowers tyrosinemia associated with nitisinone therapy of alkaptonuria.
Hughes JH; Wilson PJM; Sutherland H; Judd S; Hughes AT; Milan AM; Jarvis JC; Bou-Gharios G; Ranganath LR; Gallagher JA
J Inherit Metab Dis; 2020 Mar; 43(2):259-268. PubMed ID: 31503358
[TBL] [Abstract][Full Text] [Related]
14. Hereditary tyrosinaemia type I: from basics to progress in treatment.
Pitkänen ST; Salo MK; Heikinheimo M
Ann Med; 2000 Nov; 32(8):530-8. PubMed ID: 11127930
[TBL] [Abstract][Full Text] [Related]
15. Daily variation of NTBC and its relation to succinylacetone in tyrosinemia type 1 patients comparing a single dose to two doses a day.
Kienstra NS; van Reemst HE; van Ginkel WG; Daly A; van Dam E; MacDonald A; Burgerhof JGM; de Blaauw P; McKiernan PJ; Heiner-Fokkema MR; van Spronsen FJ
J Inherit Metab Dis; 2018 Mar; 41(2):181-186. PubMed ID: 29170874
[TBL] [Abstract][Full Text] [Related]
16. Nitisinone: new drug. Type 1 tyrosinemia: an effective drug.
Prescrire Int; 2007 Apr; 16(88):56-8. PubMed ID: 17458044
[TBL] [Abstract][Full Text] [Related]
17. Severe neurological crisis in a patient with hereditary tyrosinaemia type I after interruption of NTBC treatment.
Schlump JU; Perot C; Ketteler K; Schiff M; Mayatepek E; Wendel U; Spiekerkoetter U
J Inherit Metab Dis; 2008 Dec; 31 Suppl 2():S223-5. PubMed ID: 18500574
[TBL] [Abstract][Full Text] [Related]
18. The Effect of Various Doses of Phenylalanine Supplementation on Blood Phenylalanine and Tyrosine Concentrations in Tyrosinemia Type 1 Patients.
van Ginkel WG; van Reemst HE; Kienstra NS; Daly A; Rodenburg IL; MacDonald A; Burgerhof JGM; de Blaauw P; van de Krogt J; Santra S; Heiner-Fokkema MR; van Spronsen FJ
Nutrients; 2019 Nov; 11(11):. PubMed ID: 31752110
[TBL] [Abstract][Full Text] [Related]
19. Early nitisinone treatment reduces the need for liver transplantation in children with tyrosinaemia type 1 and improves post-transplant renal function.
Bartlett DC; Lloyd C; McKiernan PJ; Newsome PN
J Inherit Metab Dis; 2014 Sep; 37(5):745-52. PubMed ID: 24515874
[TBL] [Abstract][Full Text] [Related]
20. Blood and Brain Biochemistry and Behaviour in NTBC and Dietary Treated Tyrosinemia Type 1 Mice.
van Ginkel WG; van Vliet D; van der Goot E; Faassen MHJR; Vogel A; Heiner-Fokkema MR; van der Zee EA; van Spronsen FJ
Nutrients; 2019 Oct; 11(10):. PubMed ID: 31623189
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
